Oral etoposide in elderly previously untreated ovarian cancer patients with residual disease

International Journal of Gynecological Cancer

Volumn 7, Issue 3, 1997, Pages 213-217

  Tuxen, M K ^a   Lund, B ^b   Hansen, O P ^c   Bertelsen, K ^d   Hansen, M ^e  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b FINSEN LABORATORY   (Denmark)

^c BISPEBJERG HOSPITAL   (Denmark)

^d ODENSE UNIVERSITY HOSPITAL   (Denmark)

^e HILLERØD HOSPITAL   (Denmark)

Author keywords

Etoposide; Ovarian cancer; Phase II study

Indexed keywords

CYCLOPHOSPHAMIDE; ETOPOSIDE; MELPHALAN; TREOSULFAN;

AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; HUMAN; MINIMAL RESIDUAL DISEASE; ORAL DRUG ADMINISTRATION; OVARY CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0030787783     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1438.1997.00443.x     Document Type: Article

References (19)

1. Edmonson JH, Decker DG, Malkasian GD, Webb MJ, Jorgensen EO. Phase II evaluation of VP-16-213 (NSC-141540) in patients with advanced ovarian carcinoma resistant to alkylating agents. Gynecol Oncol 1978; 6: 7-9.
2. Maskens AP, Armand JP, Lacave AJ, De Jager RL, Hansen HH, Wolff JPM. Phase II clinical trial of VP-16-213 in ovarian cancer. Cancer Treat Rep 1981; 65: 329-30.
3. Falkson G, Van Dyk JJ, Van Eden EB, Van Der Merwe AM, Van Der Bergh JA, Falkson HC. A clinical trial of the oral form of 4'-demethyl-epipodophyllotoxin-β-D ethylidene glucoside (NSC 141540) VP 16-213. Cancer 1975; 35: 1141-4.
4. Slayton RE, Creasman WT, Petty W, Bundy B, Blessing JA. Phase II trial of VP-16-213 in the treatment of advanced squamous cell carcinoma of the cervix and adenocarcinoma of the ovary: a Gynecologic Oncology Group Study. Cancer Treat Rep 1979; 63: 2089-92.
5. Kühnle H, Achterrath W, Frischkorn R. Disease oriented phase II trial with Etoposide (NSC 141540) in cisplatin refractory ovarian cancer. Tumor Diagnostic Therapie 1984; 5: 152-5.
6. Hillcoat BL, Campbell JJ, Pepperell R, Quinn MA, Bishop JF, Day A. Phase II trial of VP-16-213 in advanced ovarian carcinoma. Gynecol Oncol 1985; 22: 162-6.
7. Bork E, Hansen M, Dombernowsky P, Hansen SW, Pedersen AG, Hansen HH. Teniposide (VM-26), an overlooked highly active agent in small-cell lung cancer. Results of a phase II trial in untreated patients. J Clin Oncol 1986; 4: 524-7.
8. WHO. Handbook for Reporting Results of Cancer Treatment. Geneva, Switzerland: World Health Organization, 1979.
9. Young RC, Chabner BA, Hubbard SP, et al. Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy. N Engl J Med 1978; 299: 1261-6.
10. Bruckner HW, Pagano M, Falkson G, et al. Controlled prospective trial of combination chemotherapy with cyclophosphamide, adriamycin, and 5-fluorouracil for the treatment of advanced ovarian cancer: a preliminary report. Cancer Treat Rep 1979; 63: 297-9.
11. Turbow MM, Jones H, Yu VK, Greenberg B, Hannigan J, Torti FM. Chemotherapy of ovarian carcinoma: a comparison of melphalan vs adriamycin-cyclophosphamide. Proc Am Assoc Cancer Res 1980; 21: 196.
12. Park RC, Blom J, Disaia PJ, Lagasse LD, Blessing JA. Treatment of women with disseminated or recurrent advanced ovarian cancer with melphalan alone in combination with 5-fluorouracil and dactinomycin or with the combination of cytoxan, 5-fluorouracil and dactinomycin. Cancer 1980; 45: 2529-42.
13. Adams M, Johansen KA, James KW, Rocker I. A controlled clinical trial in advanced ovarian cancer. Clin Radiol 1982; 33: 161-3.
14. Omura GA, Morrow CP, Blessing JA, Miller A, Buchsbaum HJ, Homesley HD, Leone L. A randomized comparison of melphalan versus melphalan plus hexamethyl-melamine versus adriamycin plus cyclophosphamide in ovarian carcinoma. Cancer 1983; 51: 783-9.
15. Fennelly J. Treosulfan (dihydroxybusulphan) in the management of ovarian carcinoma. Br J Obstet Gynaecol 1977; 84: 300-3.
16. Edmonson JH, Fleming TR, Decker DG, et al. Different chemotherapeutic sensitivities and host factors affecting prognosis in advanced ovarian carcinoma versus minimal residual disease. Cancer Treat Rep 1979; 63: 241-7.
17. Scot JS. Medical research council study on chemotherapy in advanced ovarian cancer. Medical Research Council's Working Party on Ovarian Cancer. Br J Obstet Gynaecol 1981; 88: 1174-85.
18. Carmo-Pereira J, Costa FO, Henriquese E. Moderate-dose cyclophosphamide for disseminated ovarian carcinoma: a phase II study. Eur J Cancer Clin Oncol 1983; 19: 461-5.
19. Carmo-Pereira J, Costa FO, Henriques E. Cis-Platinum, adriamycin, and hexamethylmelamine versus cyclophosphamide in advanced ovarian carcinoma. Cancer Chemother Pharmacol 1983; 10: 100-3.